daunorubicin + cytarabine + granulocyte colony-stimulating factor

**Daunorubicin + cytarabine + granulocyte colony-stimulating factor** is a chemotherapy regimen combining daunorubicin (an anthracycline that inhibits topoisomerase II, intercalates DNA, and generates free radicals to induce cytotoxicity), cytarabine (a cytidine analog that inhibits DNA polymerase and terminates DNA chain elongation during S-phase), and granulocyte colony-stimulating factor (G-CSF, a hematopoietic growth factor that stimulates neutrophil production and enhances chemotherapy tolerance by reducing neutropenia duration). Primarily used in acute myeloid leukemia (AML), this triplet regimen aims to intensify induction or reinduction therapy while mitigating myelosuppression; G-CSF is often integrated into schedules like FLAG (fludarabine + cytarabine + G-CSF, sometimes with daunorubicin or idarubicin) or similar variants for relapsed/refractory or older patients, improving response rates without excessive toxicity in clinical trials.